Heron Therapeutics, Inc. (HRTX) Lifted to Hold at BidaskClub

Heron Therapeutics, Inc. (NASDAQ:HRTX) was upgraded by research analysts at BidaskClub from a “sell” rating to a “hold” rating in a report released on Saturday.

Several other research firms have also weighed in on HRTX. Jefferies Group LLC reaffirmed a “buy” rating on shares of Heron Therapeutics in a report on Wednesday, August 16th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Heron Therapeutics in a report on Monday, June 26th. Zacks Investment Research raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective for the company in a report on Wednesday, July 12th. Cowen and Company reaffirmed a “buy” rating and set a $40.00 price objective on shares of Heron Therapeutics in a report on Friday, May 26th. Finally, Noble Financial reissued a “buy” rating on shares of Heron Therapeutics in a report on Thursday, August 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eleven have assigned a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $31.00.

Heron Therapeutics (NASDAQ:HRTX) traded down 0.91% during mid-day trading on Friday, hitting $16.40. The stock had a trading volume of 331,598 shares. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85. The company has a 50-day moving average of $15.77 and a 200-day moving average of $14.76.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Wednesday, August 9th. The biotechnology company reported ($0.80) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million for the quarter, compared to analyst estimates of $4.53 million. Equities analysts predict that Heron Therapeutics will post ($3.51) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “[[title]]” was reported by [[site]] and is the property of of [[site]]. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at [[permalink]].

Institutional investors have recently made changes to their positions in the stock. Parametric Portfolio Associates LLC boosted its position in shares of Heron Therapeutics by 2.3% in the second quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after buying an additional 771 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Heron Therapeutics by 0.6% in the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after buying an additional 1,026 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Heron Therapeutics by 13.9% in the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after buying an additional 1,098 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of Heron Therapeutics by 11.4% in the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after buying an additional 1,700 shares during the last quarter. Finally, Tudor Investment Corp ET AL boosted its position in shares of Heron Therapeutics by 10.2% in the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after buying an additional 1,724 shares during the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.